10-Q: Absci Q3 2025: Losses Widen Amid R&D Boost, ABS-101 Partner Search

Absci Corporation reports increased net losses and decreased partner revenue in Q3 2025, while advancing its AI drug creation platform and seeking a partner for its lead candidate ABS-101.

Summary

• Net loss for the three months ended September 30, 2025, increased to $28.7 million from $27.4 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $85.6 million from $74.1 million in the prior year period.
• Partner program revenue decreased by 78% to $0.4 million for the three months ended September 30, 2025, and by 44% to $2.2 million for the nine months ended September 30, 2025, compared to the respective prior year periods.
• Research and development expenses increased by 23% to $56.1 million for the nine months ended September 30, 2025, compared to $45.5 million in the prior year period.
• Cash, cash equivalents, and marketable securities totaled $152.5 million as of September 30, 2025.
• The accumulated deficit reached $595.2 million as of September 30, 2025.
• Interim results from the ABS-101 Phase 1 clinical trial demonstrated an extended half-life compared to first-generation anti-TL1A competitor programs and a favorable safety profile, but not versus next-generation programs.
• Absci will not pursue further internal clinical development of ABS-101 and will seek a partner for this asset.
• The Phase 1 clinical trial for ABS-201 was approved in Australia in October 2025, with the first participant anticipated to be dosed in December 2025.
• A strategic collaboration with Advanced Micro Devices, Inc. (AMD) in January 2025 included a $20.0 million private investment in public equity (PIPE) to optimize AI drug creation performance.
• The company raised $46.7 million in net proceeds from a common stock offering in July 2025 and $35.7 million in net proceeds from an at-the-market (ATM) offering during the nine months ended September 30, 2025.
• A contingent consideration liability of $12.75 million related to the Totient acquisition was settled for $7.6 million in October 2025, releasing $8.7 million in restricted cash.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is actively pursuing its pipeline, securing capital, and investing in R&D, the significant decline in partner revenue and widening net losses are concerning. The strategic decision to partner ABS-101, despite some positive data, suggests challenges in its competitive positioning or internal advancement capabilities. The capital raises are positive for liquidity but also highlight the ongoing need for funding given the burn rate.

Positives

• Successfully demonstrated de novo design of an antibody targeting a previously difficult-to-drug HIV epitope in collaboration with the California Institute of Technology.
• ABS-101 Phase 1 interim results showed an extended half-life compared to first-generation anti-TL1A competitor programs and a favorable safety profile with no serious adverse events reported to date.
• ABS-201 Phase 1 clinical trial approved in Australia in October 2025, with first participant dosing anticipated in December 2025, indicating pipeline progression.
• Secured a strategic collaboration with Advanced Micro Devices, Inc. (AMD) in January 2025, including a $20.0 million PIPE investment, aimed at optimizing AI drug creation performance.
• Successfully raised significant capital through a $46.7 million public offering in July 2025 and $35.7 million from an at-the-market offering during the nine months ended September 30, 2025, bolstering liquidity.
• Settled the contingent consideration liability for the Totient acquisition for $7.6 million in October 2025, which also released $8.7 million in restricted cash to the company.
• Increased research and development expenses by 23% for the nine months ended September 30, 2025, reflecting continued investment in the Integrated Drug Creation platform and internal programs.

Negatives

• Net loss increased to $28.7 million for the three months ended September 30, 2025, from $27.4 million in the prior year, and to $85.6 million for the nine months ended September 30, 2025, from $74.1 million.
• Partner program revenue significantly decreased by 78% for the three months and 44% for the nine months ended September 30, 2025, indicating a substantial decline in core revenue generation.
• The strategic decision to seek a partner for ABS-101 and not pursue further internal clinical development, despite positive safety and half-life data against first-generation competitors, suggests potential challenges in its competitive positioning against next-generation programs or internal resource allocation.
• Revenue concentration risk is high, with two partners representing approximately 93% of total partner program revenue for the three months and three partners representing 98% for the nine months ended September 30, 2025.
• The accumulated deficit grew to $595.2 million as of September 30, 2025, highlighting ongoing unprofitability.
• ABS-101's interim Phase 1 results did not demonstrate an extended half-life compared to next-generation anti-TL1A competitor programs, potentially limiting its 'best-in-class' potential.

Risks

• High degree of uncertainty regarding the initiation, timing, progress, results, and costs of both internally developed and partnered programs, including preclinical studies and clinical trials.
• Limited operating history makes it difficult to evaluate the business and predict future performance.
• Significant losses incurred since inception, with expectations of future losses and potential inability to generate sufficient revenue to achieve and maintain profitability.
• Need to raise additional capital to fund operations and improve the Integrated Drug Creation platform; inability to do so on acceptable terms or at all would harm the business.
• Biologic drug development is inherently uncertain, and the technology may not succeed in discovering appropriate molecules or producing cell lines, potentially preventing product candidates from achieving development/regulatory milestones or commercial viability.
• Unforeseen or negative events in preclinical or clinical development, regulatory approval, or commercialization could negatively affect revenue opportunities and reputation.
• Preclinical and clinical development is uncertain; product candidates may experience delays or never advance to clinical trials.
• Preliminary data and interim results from clinical trials may change as more data becomes available and are not necessarily predictive of final results or later studies.
• The biopharmaceutical platform technology market is highly competitive, and inability to compete successfully could prevent revenue growth or sustained profitability.
• Reliance on third parties to conduct preclinical studies and clinical trials; non-performance could lead to delays, increased costs, or program failure.
• Failure to achieve projected development goals in announced timeframes could delay commercialization and platform validation, increase expenses, and cause stock price decline.
• Substantial dependence on the successful application of the Integrated Drug Creation platform to initiate and advance partnered programs and develop internally developed programs.
• Partnership strategy significantly depends on the eventual approval and commercialization of product candidates developed under partnerships, over which Absci may have no control.
• Inability to maintain current partner relationships, expand existing ones, or enter into new relationships would adversely affect future operating results.
• Reliance on a limited number of suppliers for laboratory equipment and materials; difficulty finding replacements or transitioning to alternatives.
• The Integrated Drug Creation platform may not meet the expectations of partners, adversely affecting business, financial condition, results of operations, and prospects.
• Loss of any member of the senior leadership team or inability to attract and retain highly skilled scientists and business development professionals could adversely affect the business.
• Dependence on information technology systems; significant disruptions or failures could result in financial, legal, regulatory, business, and reputational harm.
• Inability to obtain and maintain sufficient intellectual property protection for technologies, or if the scope is not sufficiently broad, competitors could develop similar technologies.
• Disruptions to federal government operations (e.g., shutdowns) could prevent governmental agencies like the FDA from performing normal business functions, negatively impacting the business.
• Inability to effectively develop or commercialize product candidates could have a material adverse effect on the business and cause the market price of common stock to decline.
• Difficulty forecasting future financial performance and revenues due to the complexities and long development timelines inherent in biologic drug development.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Clinical supply and manufacturing problems could result in delays in development, approval, or commercialization.
• Uncertainty regarding medical insurance coverage and reimbursement status of newly approved therapeutics could limit partners' ability to successfully commercialize product candidates.
• Intense competition from existing drugs, new treatment methods, and new technologies in the pharmaceutical industry.
• Healthcare reform efforts aimed at lowering the price of biopharmaceutical products may impact the ability to maintain sufficient profits.
• Market skepticism regarding the viability and benefits of novel synthetic biology and AI technologies could hinder adoption by potential partners and investors.
• Inability to collect on accounts receivable from a significant number of partners may have an adverse effect on business, financial condition, and results of operations.
• If the operating facility becomes damaged or inoperable, or if required to vacate, the ability to conduct drug creation and internal R&D efforts may be jeopardized.
• Current and future use of evolving technologies, such as artificial intelligence (AI), may present risks and challenges, including cybersecurity, operational challenges, reputational harm, and potential liability.
• International expansion of the business exposes to business, regulatory, political, operational, financial, and economic risks.
• Business activities are subject to the FCPA and other anti-bribery and anti-corruption laws, as well as U.S. and foreign export controls and trade sanctions; violations could lead to liability.
• Use of biological and hazardous materials requires considerable expertise and expense for handling, storage, and disposal, and may result in claims.
• Public health crises such as pandemics or similar outbreaks could cause disruption of platform technology development and adversely impact the business.
• Reliance on a limited number of outside parties for cGMP manufacturing could delay or prevent preclinical development, clinical development, and/or commercialization efforts.
• Inability to protect and enforce trademarks and trade names, or build name recognition, could harm the competitive position.
• Claims challenging the inventorship of patents and other intellectual property could lead to substantial costs and loss of rights.
• Involvement in patent litigation or other proceedings related to a determination of rights could incur substantial costs, liability for damages, or require cessation of development/commercialization efforts.
• Obtaining and maintaining patent protection depends on compliance with various required procedures, and non-compliance could reduce or eliminate patent protection.
• Patent terms may be inadequate to protect the competitive position for an adequate amount of time.
• Jointly owned intellectual property discovered through government-funded programs may be subject to federal regulations such as march-in rights, limiting exclusive rights.
• Share price may be volatile, and investors could lose all or part of their investment.
• Potential for material weakness in internal control over financial reporting.
• Key business metrics used to evaluate the business may not accurately reflect all aspects needed for evaluations and decisions.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution of percentage ownership and cause share price to fall.
• No intention to pay dividends on common stock, limiting returns to stock value appreciation.
• Principal stockholders and management own a significant percentage of shares and can exert significant influence over matters subject to stockholder approval.
• Future sales of common stock in the public market could cause share price to fall.
• An active trading market for common stock may not continue to be maintained.
• Provisions in corporate charter documents and under Delaware law could make an acquisition more difficult and may prevent attempts by stockholders to replace or remove current management.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Ability to use net operating losses and certain other tax attributes may be limited.
• Changes in tax law may adversely affect the company or investors.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, share price and trading volume could decline.
• Unfavorable U.S. or global economic conditions could adversely affect business, financial condition, or results of operations.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations and financial condition.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies.
• Employees, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and insider trading.
• Insurance policies are expensive and protect only from some business risks, leaving exposure to significant uninsured liabilities.
• Cybersecurity incidents, data breaches, loss of data, and other disruptions could compromise sensitive information and expose to liability.
• Natural and man-made disasters, including cyber-attacks, could severely disrupt operations.
• Social media platforms present new risks and challenges to the business.
• Reduced reporting requirements applicable to emerging growth companies could make common stock less attractive to investors.
• Significant increased costs as a result of operating as a public company, and management will be required to devote substantial time to new compliance initiatives.
• Results of operations and financial condition could be materially adversely affected by changes in accounting principles.
• If estimates or judgments relating to critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, results of operations could be adversely affected.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Future Outlook

Absci expects to continue incurring significant expenses as it develops internally developed programs, scales R&D activities, executes business development strategies, acquires new technologies, and attracts highly qualified personnel. The company anticipates its current cash, cash equivalents, and marketable securities will be sufficient for at least the next 12 months. The ABS-101 Phase 1 trial is on track to complete in Q1 2026, after which the company will seek a partner for the asset. The ABS-201 Phase 1 clinical trial is expected to dose its first participant in December 2025, with interim data anticipated in the second half of 2026, and a Phase 2 trial for endometriosis expected to initiate in late 2026 with potential interim data in the second half of 2027. Research and development expenses are projected to increase in absolute dollars over the long term.

Management Comments

• "We are a clinical-stage biopharmaceutical company advancing potential breakthrough antibody therapeutics with generative AI."
• "Leveraging our synthetic biology roots, we expect our Integrated Drug Creation platform to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit."
• "Through these efforts, we aim to shorten time to clinic, while increasing the probability of success."
• "Our approach expands the possibilities in biopharmaceuticals — shifting from a paradigm of drug discovery to drug creation — with the goal of bringing best-in-class and first-in-class antibody therapeutics to the patients who need them."
• "We believe that by developing our own pipeline, we will create optionality for enhanced monetization and validation of our Integrated Drug Creation platform."
• "Our evolving business model is underpinned by our Integrated Drug Creation platform which supports a strategic diversification of our program portfolio through internally developed programs, partnered drug creation programs and co-development programs."
• "We believe that our cash, cash equivalents and marketable securities will be sufficient to meet our operating expenses, working capital and capital expenditure needs over at least the next 12 months following the date of this filing."

Industry Context

Absci operates in the highly competitive biopharmaceutical platform technology market, specifically focusing on AI-powered biologic drug design. The company faces competition from other AI-driven drug discovery firms (e.g., Generate Biomedicines, Xaira Therapeutics), companies in adjacent AI-enabled small molecule design (e.g., Recursion Pharmaceuticals, Schrodinger), and traditional pharmaceutical and biotechnology companies. The broader antibody therapeutic market is growing, but the industry faces significant challenges in drug development and commercialization. Absci's strategy to use AI aims to accelerate drug discovery and improve success rates. The company's internal pipeline, including ABS-101 for IBD and ABS-201 for AGA/endometriosis, competes with numerous established and emerging therapies from larger pharmaceutical players. The industry is also subject to evolving regulatory landscapes, including potential impacts from changes in U.S. presidential administrations, FDA staffing, and new legislation like the Inflation Reduction Act and the One Big Beautiful Bill Act, which influence drug pricing and orphan drug designations. Additionally, the increasing focus on AI regulation (e.g., EU's AI Act, state-level U.S. laws) introduces new compliance burdens and potential legal risks for companies leveraging these technologies.

Comparison to Industry Standards

• ABS-101 interim Phase 1 results showed an extended half-life compared to first-generation anti-TL1A competitor programs, but not versus next-generation programs, suggesting it may not be a leading candidate in its class compared to more advanced industry competitors.
• The company's goal to "shorten time to clinic, while increasing the probability of success" using its AI platform is an industry-wide aspiration, but the filing does not provide specific comparative data against global benchmarks or comparable projects to demonstrate superior performance in this regard.
• The high failure rate in drug development, where "most product candidates that commence clinical trials are never approved," is acknowledged, aligning with general industry standards for the inherent risks in biopharmaceutical R&D.
• Absci's business model, relying on downstream payments (milestones and royalties) from partners, is a common approach for platform technology companies; however, the absence of any partner having yet entered into a license for clinical or commercial use of intellectual property related to a product candidate indicates a lack of commercial validation compared to more mature platform companies that have achieved such milestones.

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or other legal proceedings.

Related Party Transactions

• In January 2025, Absci entered into a strategic collaboration with Advanced Micro Devices, Inc. (AMD), which included AMD purchasing 5,714,285 shares of Absci's common stock for net proceeds of $20.0 million through a private investment in public equity (PIPE). The issuance was at a premium of approximately $2.5 million over the market price, recorded as a credit to research and development expense over the collaboration term.

Stakeholder Impact

• Shareholders face potential dilution from recent and future equity offerings, and the stock price may be volatile due to financial performance, program updates, and market conditions. The influence of principal stockholders and management is significant.
• Employees may benefit from continued investment in R&D and platform development, suggesting growth opportunities, but the company also faces intense competition for skilled personnel, particularly in AI-powered drug discovery.
• Customers and partners may be impacted by the decreased partner program revenue, indicating potential challenges in securing new contracts or advancing existing ones. High revenue concentration from a limited number of partners poses a risk.
• Suppliers face risks due to Absci's reliance on a limited number of providers for laboratory equipment and materials, which could lead to supply chain disruptions if alternatives are not readily available.
• Creditors are subject to the terms and covenants of equipment financing agreements, which restrict operating activities and require repayment in the event of default, potentially impacting the company's financial flexibility.

Next Steps

• Complete the ABS-101 Phase 1 clinical trial in the first quarter of 2026.
• Seek a partner for ABS-101, exploring first-in-class indications outside of Inflammatory Bowel Disease (IBD).
• Dose the first participant in the ABS-201 Phase 1 clinical trial in December 2025.
• Anticipate an interim data read-out for the ABS-201 Phase 1 clinical trial in the second half of 2026.
• Anticipate initiating a Phase 2 clinical trial for ABS-201 in patients with endometriosis in late 2026.
• Potential interim data readout for the ABS-201 Phase 2 clinical trial in the second half of 2027.
• Continue to develop internally developed programs across diverse indications, advancing product candidates through preclinical and clinical development.
• Continue to engage in discovery, research, and development efforts and scale activities to meet potential demand from new and existing partners.
• Execute an effective business development strategy to drive adoption of the Integrated Drug Creation platform and identify partners for internally developed programs.
• Develop, acquire, in-license, or otherwise obtain technologies that enable the expansion of Integrated Drug Creation platform capabilities.
• Attract, retain, and motivate highly qualified personnel.
• Continue to assess computational needs and strategically invest in infrastructure, including access to compute via cloud computing arrangements.

Key Dates

Recommendation

Absci is in a critical phase, balancing significant investment in its AI platform and internal pipeline with widening net losses and a substantial decline in partner revenue. While recent capital raises provide necessary liquidity, the strategic decision to seek a partner for its lead clinical asset, ABS-101, rather than advancing it internally, introduces uncertainty regarding its commercial path and the company's ability to independently bring assets to market. The high-risk, high-reward nature of biopharmaceutical AI development, coupled with current financial headwinds and revenue concentration, suggests a 'Hold' recommendation. Investors should await clearer signs of sustained commercial traction, successful pipeline progression for ABS-201, and a more defined path to profitability before making further investment decisions.

Keywords

Biopharmaceutical, AI drug discovery, Antibody therapeutics, Generative AI, Preclinical development, Clinical trials, Inflammatory Bowel Disease, Androgenic alopecia, TL1A, PRLR, AMD collaboration, PIPE, SEC filing, 10-Q, Financial results, Research and development, Capital raise, Stock offering, Corporate governance, Risk factors, Biologics market